^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iparomlimab (QL1604)

    i
    Other names: QL1604, PSB103, QL-1604, QL 1604
    Company:
    Qilu Pharma
    Drug class:
    PD1 inhibitor
    Related drugs:
    21h
    Myocarditis induced by a novel bifunctional PD-1/CTLA-4 combination antibody: a case report and literature review. (PubMed, BMC Cardiovasc Disord)
    We report the first documented case of myocarditis linked to the novel bifunctional PD-1/CTLA-4 combination, Iparomlimab and Tuvonralimab. This case highlights that structural drug optimizations do not preclude severe cardiotoxicity. In resource-limited settings lacking advanced imaging, serial high-sensitivity troponin monitoring served as the cornerstone for early detection and guiding management. This experience confirms that favorable outcomes are achievable through vigilant biomarker surveillance and coordinated multidisciplinary care, even without advanced diagnostics.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • ICOS (Inducible T Cell Costimulator)
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1d
    Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Lenvima (lenvatinib) • Inlyta (axitinib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    9d
    Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer (clinicaltrials.gov)
    P2, N=29, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Lenvima (lenvatinib) • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    25d
    Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    cisplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    Exploring the efficacy and safety of famitinib combined with epalrestat and torivirine in the treatment of advanced and recurrent/metastatic cervical cancer (ChiCTR2500111354)
    P2, N=90, Not yet recruiting, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    famitinib (SHR 1020) • iparomlimab (QL1604)
    1m
    An exploratory study on tuvonralimab/iparomlimab combined with chemotherapy for the treatment of advanced non-small cell lung cancer patients with EGFR uncommon mutations (ChiCTR2500111278)
    P=N/A, N=20, Not yet recruiting, Cancer Hospital, Chinese academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences
    New trial
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    A single-arm, multicenter, exploratory clinical study on the third-line treatment of metastatic colorectal cancer with Iparomlimab and Tuvonralimab combined with anti-angiogenic drugs (ChiCTR2500110241)
    P4, N=44, Not yet recruiting, Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital
    New P4 trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    Iparomlimab and Tuvonralimab combined with irinotecan liposome is used in recurrent/metastatic nasopharyngeal carcinoma after anti-PD - (L) 1 monoclonal antibody treatment (ChiCTR2500110090)
    P2, N=36, Not yet recruiting, Chongqing University Cancer Hospital; Chongqing University Cancer Hospital
    New P2 trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    A Single-Center, Single-Arm, Phase II Study of QL1706 (Iparomlimab and Tuvonralimab Injection) in Combination with Chemotherapy and Anti-angiogenic Therapy in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Failed Prior Platinum-Based Chemotherapy (ChiCTR2500110068)
    P2, N=30, Not yet recruiting, The Second Affiliated Hospital Zhejiang University School of Medicine; The Second Affiliated Hospital Zhejiang University School of Medicine
    New P2 trial
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    A Single-Arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer (ChiCTR2500109864)
    P2, N=42, Not yet recruiting, Qilu Hospital of Shandong University(Qingdao); Qilu Hospital of Shandong University(Qingdao)
    New P2 trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    A Single-Center, Single-Arm Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined with Platinum-Based Chemotherapy as Neoadjuvant Therapy for Non-Small Cell Lung Cancer (ChiCTR2500109309)
    P=N/A, N=10, Not yet recruiting, Tianjin Medical University General Hospital; Tianjin Medical University General Hospital
    New trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    Exploratory clinical study of Iparomlimab and Tuvonralimab (QL1706) in combination with albumin paclitaxel and nedaplatin for locally advanced resectable squamous cell carcinoma of the esophagus (ESCC) (ChiCTR2500109130)
    P=N/A, N=30, Not yet recruiting, Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
    New trial
    |
    albumin-bound paclitaxel • Aqupla (nedaplatin) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)